Exenatide

≥98% HPLCCOA per batchCold-chain shippedIn-house synthesisResearch use only · not for human consumption

Price range: $74.99 through $119.99

Independently verified Tested by IRZC Laboratories Batch NHV26-P5340 · Purity 98.61 % HPLC · Issued 4 Aug 2026 · Cert COA-AKMP-0N1Z-FVerify at IRZCVerifyScan to verify

The first FDA-approved GLP-1 agonist derived from Gila monster venom, available as twice-daily and once-weekly formulations.

FormulaC184H282N50O60S
Mol. weight4186.63 g/mol
FormLyophilised powder
0 People watching this product now!
SKU: PEP-018 Category:

Molecular & analytical data

Verified chemistry and third-party reference identifiers for this compound.

Amino acid sequence39-amino-acid peptide based on exendin-4 from Heloderma suspectum
Molecular formulaC184H282N50O60S
Molecular weight4186.63 g/mol
CAS number141758-74-9
PubChem CIDCID 45588096 ↗
UniProt IDP26349 (Exendin-4, Heloderma suspectum)
Purity standard≥98%
Half-life~2.4 hours (immediate release); ~2 weeks (extended release microspheres)
BioavailabilitySubcutaneous: moderate
Origin / sourceSynthetic; based on exendin-4 from Gila monster saliva. Manufactured by AstraZeneca.
Year discoveredFDA approved 2005 (Byetta)
Exenatide molecular structure
2D structure · source: PubChem

Reconstitution calculator

Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →

Concentration— mg/mL— mcg per unit
—Draw tounits on a U-100 syringe
—Volume / drawmL
—Complete drawsper vial

—

A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.

Quality & verification

Every batch is characterised before release and ships with documentation.

≥98%HPLC purity
4186.63 g/molMolecular weight
MS + HPLCIdentity & purity assay
Third-party testedBatches are tested by IRZC Laboratories — independent HPLC + mass-spec confirms identity and purity against that product’s release specification.
Batch-matched COAA certificate of analysis is issued per batch and matched to your vial’s lot number.
Cold-chain fulfilmentLyophilised product is packed with insulated, temperature-controlled shipping.
Controlled synthesisProduced under documented, reproducible in-house processes with lot traceability.

Storage & handling

Keep the peptide stable from delivery through reconstitution.

1
On arrivalStore the sealed, lyophilised vial frozen at −20°C, protected from light and moisture.
2
ReconstitutionAdd bacteriostatic water down the vial wall; swirl gently — do not shake. Use the calculator above to plan volume.
3
After mixingRefrigerate the reconstituted solution at 2–8°C and use within the stability window below.
4
HandlingWork in a clean area, wipe the stopper with alcohol, and avoid repeated freeze–thaw cycles.
Manufacturer storage note

Refrigerate at 2-8°C.

Description

Exenatide was the first GLP-1 receptor agonist approved by the FDA (2005). It is a synthetic version of exendin-4, a hormone originally discovered in the saliva of the Gila monster lizard. Available as Byetta (twice-daily injection) and Bydureon (once-weekly extended-release injection). While newer GLP-1 agents have surpassed it in convenience and efficacy, exenatide played a pioneering role in establishing the GLP-1 drug class and remains in clinical use.

Certificates of Analysis

Certificates of Analysis

Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.

Batch #IssuedPurityCertificate
NHV26-P5340
COA-AKMP-0N1Z-F
04 Aug 202698.61 % HPLCVerify at IRZC ↗

“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.

Research & Literature
Reported in research literature — not usage guidance.

The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.

Mechanism of action

GLP-1 receptor agonist (exendin-4 backbone), glucose-dependent insulin stimulation, glucagon suppression, delayed gastric emptying, appetite reduction.

Primary uses / indications

Type 2 diabetes management

Typical dosage (reported)

Byetta: 5-10 mcg twice daily before meals. Bydureon: 2 mg once weekly.

Cycle duration (reported)

Long-term ongoing treatment

Administration route

Subcutaneous injection (twice daily or once weekly depending on formulation)

Side effects (reported)

Nausea, vomiting, diarrhea, dizziness, headache, jittery feeling, injection site reactions (nodules with Bydureon).

Contraindications

MTC/MEN 2 (Bydureon), severe renal impairment, personal history of pancreatitis, pregnancy

Drug interactions

Potentiates hypoglycemia with sulfonylureas. Affects gastric emptying and oral drug absorption.

Reviews (0)
0 reviews
0
0
0
0
0

There are no reviews yet.

Be the first to review “Exenatide”

Your email address will not be published. Required fields are marked *

You have to be logged in to be able to add photos to your review.

Specifications

Identity

Full name / brand namesExenatide (Byetta, Bydureon)
CategoryGLP-1 Receptor Agonists
SubcategoryExendin-4 Based GLP-1 Agonist
Origin / sourceSynthetic; based on exendin-4 from Gila monster saliva. Manufactured by AstraZeneca.
Year discoveredFDA approved 2005 (Byetta)

Chemistry

Amino acid sequence39-amino-acid peptide based on exendin-4 from Heloderma suspectum
Molecular formulaC184H282N50O60S
Molecular weight4186.63 g/mol
CAS number141758-74-9
PubChem CIDCID 45588096 ↗
UniProt IDP26349 (Exendin-4, Heloderma suspectum)
Purity standard≥98%

Pharmacokinetics

Half-life~2.4 hours (immediate release); ~2 weeks (extended release microspheres)
BioavailabilitySubcutaneous: moderate

Regulatory & research status

FDA statusFDA-Approved. Byetta (2005), Bydureon (2012) for type 2 diabetes.
Prescription requiredYes — prescription required
Research statusFDA-approved; well-established drug with long-term safety data.
Clinical trialsNCT00308139 (DURATION-1); FDA-approved (Byetta 2005, Bydureon 2012)

References

Holst JJ, "The physiology of glucagon-like peptide 1", Physiological Reviews, 2007, DOI: 10.1152/physrev.00034.2006; Drucker DJ et al., "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes", Lancet, 2008, DOI: 10.1016/S0140-6736(08)61206-4

Frequently asked questions

What is Exenatide?
The first FDA-approved GLP-1 agonist derived from Gila monster venom, available as twice-daily and once-weekly formulations.
How does Exenatide work?
Reported in the research literature: GLP-1 receptor agonist (exendin-4 backbone), glucose-dependent insulin stimulation, glucagon suppression, delayed gastric emptying, appetite reduction.
What Exenatide dosage is used in research?
For laboratory research reference only, not usage guidance: Byetta: 5-10 mcg twice daily before meals. Bydureon: 2 mg once weekly.
What is the half-life of Exenatide?
The reported biological half-life of Exenatide is approximately ~2.4 hours (immediate release); ~2 weeks (extended release microspheres).
How should Exenatide be stored and reconstituted?
NHOV ships Exenatide as a lyophilised powder. Store unopened vials at −20 °C. Reconstitute with bacteriostatic water; once reconstituted, refrigerate at 2–8 °C, protect from light, and use within the bacteriostatic-water shelf window. Use the NHOV reconstitution calculator to find the exact volume for your target concentration.
What purity is NHOV's Exenatide?
NHOV Exenatide is released against a specification of ≥98%, verified by HPLC with mass-spectrometry identity confirmation, and ships with a batch-specific Certificate of Analysis (COA) matched to the vial's lot number.
Is Exenatide approved for human use?
No. Exenatide is sold strictly for laboratory and scientific research use only. It is not for human or veterinary consumption and is not approved as a drug.